Wired concludes that investing in healthy life extension ventures is much like investing in the rest of biotechnology - a risky proposition. "Plowing cash into companies pursuing remedies for the ravages of age isn't the safest prescription for investors' financial well being. Biotechnology, the industry that promises the broadest potential for life-extending breakthroughs, is a notoriously risky investment play ... Still, investors [have time] to be patient. If it all works out, and we really do live forever, that should provide plenty of time for a portfolio of biotechnology stocks to turn a profit." It seems to me that biotech stocks over the past decade or so look much like early computer industry stocks - all very much a roll of the dice. It stopped being that way, you may recall, as the industry matured.

Link: http://www.wired.com/news/print/0,1294,68073,00.html